The Core HTA is available online at the Core Model Online Tool here. Relevant document can be found as a pdf below.
The aim of this core HTA was to compare Immunoglobulins (IGG) to placebo, not doing anything or Usual supportive care in the treatment of Alzheimer’s disease in elderly.
Agenas, Italy is the editor of this joint assessment and the editorial team consists of GOG, HVB, ASSR RER,CEM, NCPHA, INFARMED.
AD is diagnosed mostly in people over 65 years of age, although there is an early-onset form that can occur much earlier. According to Wikipedia in 2006, there were 26.6 million sufferers worldwide.
Like all dementias, Alzheimer’s Disease is an important global public health problem.
Immunoglobulins, traditionally used to prevent or treat infectious diseases have been recently used for other non-communicable conditions including rare neurological diseases.
We report on reviews of the evidence of use and effect of immunoglobulins for Alzheimer’s Disease and Mild Cognitive Impairment. The existence and significance of Mild Cognitive Impairment are still debated.
The Core HTA is available online at the Core Model Online Tool here. Relevant document can be found as a pdf below.
Intravenous immunoglobulins for Alzheimer’s disease_Core HTA 2_Final_Nov 2015
